BLENOXANE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Blenoxane, and when can generic versions of Blenoxane launch?
Blenoxane is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in BLENOXANE is bleomycin sulfate. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bleomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Blenoxane
A generic version of BLENOXANE was approved as bleomycin sulfate by HOSPIRA on March 10th, 2000.
Summary for BLENOXANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 21 |
| Clinical Trials: | 21 |
| Patent Applications: | 5,174 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | BLENOXANE at DailyMed |
Recent Clinical Trials for BLENOXANE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The EMMES Corporation | Phase 1 |
| University of California, Los Angeles | Phase 1 |
| The Emmes Company, LLC | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for BLENOXANE
US Patents and Regulatory Information for BLENOXANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | BLENOXANE | bleomycin sulfate | INJECTABLE;INJECTION | 050443-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bristol Myers Squibb | BLENOXANE | bleomycin sulfate | INJECTABLE;INJECTION | 050443-002 | Sep 7, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
